- Home
- DSU vs KALV Comparison
DSU vs KALV Comparison
Compare DSU & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DSU | KALV |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 548.1M | 551.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DSU | KALV |
|---|---|---|
| Price | $10.28 | $16.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.43 |
| AVG Volume (30 Days) | 148.2K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,426,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $204.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.22 | $7.30 |
| 52 Week High | $11.40 | $17.28 |
Technical Indicators
Market Signals| Indicator | DSU | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 71.97 |
| Support Level | $10.22 | $13.28 |
| Resistance Level | $10.34 | $14.51 |
| Average True Range (ATR) | 0.07 | 1.15 |
| MACD | 0.01 | 0.21 |
| Stochastic Oscillator | 71.71 | 90.20 |
Price Performance
Historical ComparisonAbout DSU Blackrock Debt Strategies Fund Inc.
Blackrock Debt Strategies Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income by investing in a diversified portfolio of U.S. companies' debt instruments including corporate loans. The fund's secondary investment objective is to provide capital appreciation.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.